



Cite this: *Chem. Commun.*, 2014, 50, 12325

Received 9th June 2014,
Accepted 21st August 2014

DOI: 10.1039/c4cc04344h

www.rsc.org/chemcomm

Spermidinium *closo*-dodecaborate-encapsulating liposomes as efficient boron delivery vehicles for neutron capture therapy†

Shoji Tachikawa,^{ab} Tatsuro Miyoshi,^b Hayato Koganei,^b Mohamed E. El-Zaria,^{bc} Clara Viñas,^d Minoru Suzuki,^e Koji Ono^e and Hiroyuki Nakamura^{*ab}

***closo*-Dodecaborate-encapsulating liposomes were developed as boron delivery vehicles for neutron capture therapy. The use of spermidinium as a counter cation of *closo*-dodecaborates was essential not only for the preparation of high boron content liposome solutions but also for efficient boron delivery to tumors.**

Boron neutron capture therapy (BNCT) has been attracting growing interest as one of the minimally invasive cancer therapies.¹ Mercaptoundecahydrododecaborate (Na₂[B₁₂H₁₁SH]; Na₂BSH) and *L*-*p*-boronophenylalanine (*L*-BPA) have been used in BNCT for many years. *L*-BPA, in particular, has been widely used for the treatment of not only melanoma but also brain tumor² and head and neck cancer³ because it can be taken up selectively by tumor cells through an amino acid transporter.⁴ The accelerator-based BNCT is now undergoing phase I clinical study for the treatment of brain tumor and head and neck cancer patients in Japan.^{5,6}

In recent years, liposomal ¹⁰B carriers have attracted attention as some of the efficient boron delivery systems in BNCT.^{7–10} Several efficient *in vivo* BNCTs have been reported. Yanagié and coworkers demonstrated the first antitumor effect of Na₂BSH-encapsulating liposomes conjugated with a monoclonal antibody specific for the carcinoembryonic antigen.^{9a,b} Maruyama and co-workers developed transferrin-conjugating Na₂BSH-encapsulating liposomes.^{9d,10} Although they succeeded in completely suppressing tumor growth in mice after neutron irradiation, the concentration of inner ¹⁰B of liposomes was limited in preparation due to osmotic reasons. For this reason, boron lipids embedded within the liposome

bilayer have been studied.^{10–12} Hawthorne and coworkers developed liposomes incorporating Na₃[1-(2-B₁₀H₉)-2-NH₃B₁₀H₈] into the internal aqueous core and K[*nido*-7-CH₃(CH₂)₁₅-7,8-C₂B₉H₁₁] into the bilayer membrane to increase the boron content in liposomes.^{8b,13}

We previously developed Na₂BSH-encapsulating 10% distearoyl boron lipid (DSBL)^{11b} liposomes that have high boron content with excellent boron delivery efficacy to tumors.¹⁴ In this communication, we studied the effects of the counter cations of boron clusters on liposome formation to develop high boron content liposomes for BNCT by overcoming osmotic pressure limitations.

We selected three *closo*-dodecaborates, Na₂[B₁₂H₁₂], Na₂[B₁₂H₁₁OH]¹⁵ and Na[B₁₂H₁₁NH₃]¹⁶ in addition to Na₂BSH (Fig. 1). We first tested the cytotoxicity of the *closo*-dodecaborates toward colon 26 cells. The *closo*-dodecaborates are relatively non-toxic and the GI₅₀ values of Na₂[B₁₂H₁₂], Na₂BSH, Na[B₁₂H₁₁NH₃], and Na₂[B₁₂H₁₁OH] are 5.1, 2.1, 32.9, and 7.7 mM, respectively (Table S1 in the ESI†). Liposomes containing the *closo*-dodecaborates were prepared from DSPC, cholesterol, and DSPE-PEG2000 by the reverse phase evaporation method with sizes of approximately 100 nm in diameter. The results are summarized in Table 1. The final boron and phosphorus concentrations of liposome solution containing Na₂[B₁₂H₁₂] were 3438 ± 2.0 and 2864 ± 18.3 ppm, respectively, and the B/P ratio was 1.2 (entry 1). The higher B/P ratio indicates the higher boron content in liposomes. The liposome yield was 58% based on the total phospholipids used in the preparation. The B/P ratio of the liposome containing Na[B₁₂H₁₁NH₃] was 2.2 (entry 2), which was slightly higher than those of liposomes containing Na₂BSH, Na₂[B₁₂H₁₁OH], and Na₂[B₁₂H₁₂] (1.2–1.6, entries 1, 3, and 4). In the case of Na[B₁₂H₁₁NH₃], an ammonium ion group served as one of the two counter cations of the *closo*-dodecaborate

^a Chemical Resources Laboratory, Tokyo Institute of Technology, 4259 Nagatsuta-cho, Midori-ku, Yokohama 226-8503, Japan.

E-mail: hiro@res.titech.ac.jp; Fax: +81 45 924 5244

^b Department of Chemistry, Faculty of Science, Gakushuin University, Mejiro, Toshima-ku, Tokyo 171-8588, Japan

^c Department of Chemistry, Faculty of Science, Tanta University, 31527-Tanta, Egypt

^d Institut de Ciència de Materials de Barcelona (ICMAB-CSIC), Campus U.A.B., 08193 Bellaterra, Barcelona, Spain

^e Particle Radiation Oncology Research Center, Kyoto University Research Reactor Institute, Asashiro-nishi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan

† Electronic supplementary information (ESI) available: Experimental details and data. See DOI: 10.1039/c4cc04344h





Fig. 1 Structures of *closo*-dodecaborates used for encapsulation in liposomes.



Table 1 Physical characteristics of liposomes containing *closo*-dodecaborates associated with sodium and various ammonium cations^a


Entry	Boron cluster	B conc. ^{b,c} (ppm)	P conc. (ppm)	B/P ^{b,c}	Yield ^d (%)
1	Na ₂ BSH	3438 ± 2.0	2864 ± 18.3	1.2	58
2	Na[B ₁₂ H ₁₁ NH ₃]	4072 ± 22.8	1835 ± 38.5	2.2	44
3	Na ₂ [B ₁₂ H ₁₁ OH]	2635 ± 184.2	1600 ± 99.0	1.5	39
4	Na ₂ [B ₁₂ H ₁₂]	3133 ± 10.3	1932 ± 13.3	1.6	47
5	(<i>n</i> -C ₃ H ₇ NH ₃) ₃ BSH	2874 ± 47.7	2225 ± 15.8	1.3	54
6	(H ₃ NC ₄ H ₈ NH ₃)BSH	4711 ± 17.4	1833 ± 43.4	2.6	44
7	spd-BSH	13 867 ± 185.8	4046 ± 18.3	3.4	98
8	(Sperminium)BSH	9759 ± 139.6	3559 ± 44.5	2.7	87
9	spd-[B ₁₂ H ₁₁ NH ₃]	13 970 ± 216.5	3943 ± 43.4	3.5	95



^a In all cases, liposomes were prepared from DSPC, cholesterol, and DSPE-PEG2000 (1 : 1 : 0.11, molar ratio) by the REV method. ^b Data are expressed as means ± standard deviation (SD). ^c Boron and phosphorus concentrations of liposome solution were determined by ICP-AES. ^d Liposome yields were calculated from the phosphorus concentration of liposome solution based on the total phospholipids used in preparation.


dianion. We speculated that ammonium counter cations would affect the encapsulation of *closo*-dodecaborates in liposomes. Recently, Gabel and coworkers reported that Na₂BSH induces aggregation and membrane rupture, increasing wall thickness of the liposome and triggering the release of liposome contents.¹⁷ Indeed, it is known that tetramethylammonium (TMA) salts of *closo*-dodecaborates are insoluble in water, and the ion-exchange from Na₂BSH to (TMA)₂BSH proceeds readily, whereas the ion-exchange from (TMA)₂BSH to Na₂BSH is not easy. We predicted that encapsulation as well as liposome yield would be increased if we could reduce this interaction in the preparation of *closo*-dodecaborate-encapsulating liposomes. Thus we prepared various ammonium salts of BSH and examined their encapsulation into liposomes (entries 5–9 in Table 1). The B/P ratio of the liposome containing the *n*-C₃H₇NH₃⁺ salt of BSH was similar to that of the liposome containing Na₂BSH (entries 1 vs. 5). The H₃N⁺C₄H₈NH₃⁺ cation increased the B/P ratio (2.6) and boron concentration (4711 ppm). Interestingly, the B/P ratio dramatically increased to 3.4 when the spermidinium (spd) cation was employed (entry 7). In addition, the liposome yield was markedly increased to 98% and the final boron concentration of the liposome solution reached 13 867 ppm. In contrast, the B/P ratio of liposome containing (sperminium) BSH dropped to 2.7, although the liposome yield was still high (87% yield) and the final boron concentration of the liposome solution was high at 9759 ppm (entry 8). Liposome containing spd-[B₁₂H₁₁NH₃]²⁻ showed the highest B/P ratio (3.5); the boron concentration of the liposome solution reached 13 790 ppm and the liposome yield was 95% (entry 9).

We examined whether the formation of high boron content liposomes is affected by the viscosity of the *closo*-dodecaborate solutions. However, the spd cation of [B₁₂H₁₂]²⁻ does not affect the viscosity of internal aqueous solution of liposomes (Table S3, ESI[†]). We measured liposome yields and B/P ratios under the condition of various ratios of BSH to spd cations [Na₂BSH : [spermidine + HCl]] = 1 : X, X = 0, 0.25, 0.5, 1, and 2). As shown in Fig. 2, the B/P ratio

**Fig. 2** Effect of the amount of spd cation on spd-BSH encapsulation in liposomes. Boron/phosphorus (B/P) ratios of (spd)_x-*closo*-dodecaborate-encapsulating liposomes are shown in the vertical axis.

reached a maximum of 3.4 when the BSH:spd ratio was 1 : 1. Liposome yields showed a similar tendency to B/P ratios. The highest liposome yield was observed at the BSH to spd cation ratio of 1 : 1. Transmission electron microscopy (TEM) analysis of spd-BSH-encapsulating liposomes and Na₂BSH-encapsulating liposomes was also carried out using Cryo-TEM (Fig. 3). It is notable that the liposomes interacted with each other in the case of Na₂BSH-encapsulating liposomes, whereas the liposomes dispersed in solution without interacting with each other in the case of spd-BSH-encapsulating liposomes.

We next examined boron distribution of the spd-*closo*-dodecaborate-encapsulating liposomes in colon 26 tumor-bearing mice.¹⁸ The liposomes were injected at doses of 15, 30, and 100 mg [B] kg⁻¹ body weight *via* the tail veins. Na₂BSH- and Na₂[B₁₂H₁₁NH₃]-encapsulating liposomes were also injected at a dose of 30 mg [B] kg⁻¹ as control experiments. The time courses of boron distribution in each organ are shown in Fig. 4. Blood boron concentrations of 460.7, 104.0, and 33.2 ppm were detected 24 h after injection of spd-BSH-encapsulating liposomes (100, 30, and 15 mg [B] kg⁻¹), respectively (Fig. 4a). Blood boron concentration in mice injected with 100 mg [B] kg⁻¹ of spd-BSH-encapsulating liposomes did not decrease notably during the 48 h period, whereas those in mice injected with 30 and 15 mg [B] kg⁻¹ of spd-BSH-encapsulating liposomes gradually decreased in a time-dependent manner. The time courses of boron concentrations in liver, kidneys, and spleen are shown in Fig. 4b–d, respectively. Boron concentrations of 528.5, 144.2, and 74.4 ppm in liver were observed 48 h after the injection of 100, 30, and 15 mg [B] kg⁻¹ of spd-BSH-encapsulating liposomes, respectively. In the meantime, maximum

**Fig. 3** TEM images of Na₂BSH-encapsulating liposomes (left) and spd-BSH-encapsulating liposomes (right). Scale bar represents 200 nm.




Fig. 4 Time courses of distribution of spd-BSH- and Na₂BSH-encapsulating liposomes (Δ, spd-BSH: 15 mg [B] kg⁻¹; ◇, spd-BSH: 30 mg [B] kg⁻¹; ○, spd-BSH: 100 mg [B] kg⁻¹; ▲, Na₂BSH: 15 mg [B] kg⁻¹). Each liposome was injected into tumor-bearing mice *via* the tail vein. Data are expressed as means ± SD (*n* = 5).

tumor boron concentrations of 202.7 and 82.4 ppm were achieved 36 h after injection at doses of 100 and 30 mg [B] kg⁻¹, respectively. Even at the low boron dose of 15 mg [B] kg⁻¹, the tumor boron concentration was 34.0 ppm at 36 h after injection (Fig. 4e). We also demonstrated the boron distribution of Na₂BSH-encapsulating liposomes in tumor-bearing mice for comparison. Although blood and liver boron concentrations after injection of Na₂BSH-encapsulating liposomes at a dose of 30 mg [B] kg⁻¹ were similar to those after injection of spd-BSH-encapsulating liposomes up to 48 h. The tumor boron concentration at 36 h after injecting Na₂BSH-encapsulating liposomes was 31.9 ppm, although the clearance of Na₂BSH-encapsulating liposomes was slow (Fig. 4e).

A similar tendency was observed in spd-[B₁₂H₁₁NH₃]-encapsulating liposomes (Fig. S1, ESI[†]). Blood, kidney, and spleen boron concentrations gradually decreased after injection. Maximum tumor boron concentrations of 242.2, 88.7, and 35.4 ppm were achieved 6 h after injection at doses of 100, 30, and 15 mg [B] kg⁻¹, respectively. Interestingly, significant tumor boron accumulation was also observed in the case of Na[B₁₂H₁₁NH₃]-encapsulating liposomes.

Finally, we examined the antitumor effect of liposomes containing spd *closo*-dodecaborates in colon 26 tumor bearing mice exposed to thermal neutron irradiation. Thermal neutron irradiation of the tumor-transplanted left thighs of mice was carried out 36 h after injection. The tumor growth curves of mice are shown in Fig. 5 (and in Fig. S2, ESI[†]). “Hot control (-●-)” and “Cold control (-×-)” represent tumor volumes of mice injected with saline with and without thermal neutron irradiation, respectively. Tumor growth was significantly suppressed in mice treated with spd-[¹⁰B]- and spd-[¹⁰B₁₂H₁₁NH₃]-encapsulating liposomes at doses of 15, 30, and 100 mg [¹⁰B] kg⁻¹ and exposed to thermal neutron irradiation. The tumor completely disappeared within three weeks even when a dose of 15 mg [¹⁰B] kg⁻¹ was employed. Liposomes containing Na₂[¹⁰B] and Na[¹⁰B₁₂H₁₁NH₃]




Fig. 5 Tumor volumes in mice (Balb/c, female, six weeks old, 14–20 g) bearing colon 26 solid tumor, exposed to thermal neutron irradiation (hot) for 50 min ($1.3\text{--}2.2 \times 10^{12}$ neutrons per cm²) or not exposed to thermal neutron irradiation (cold). Irradiation was performed 36 h after injection of liposomes containing spd-[¹⁰B] (Δ, 15; ◇, 30; ○, 100 mg [¹⁰B] kg⁻¹) and Na₂[¹⁰B] (◆, 30 mg [¹⁰B] kg⁻¹), or 1 h after injection of Na₂[¹⁰B] solution (■, 100 mg [¹⁰B] kg⁻¹). ●, hot control; ×, cold control. ***P* < 0.01, compared with hot control.

also inhibited tumor growth at a dose of 30 mg [¹⁰B] kg⁻¹, and the tumor was completely controlled three weeks after thermal neutron irradiation. Tumor growth was suppressed in mice treated with Na₂[¹⁰B] solution (100 mg [¹⁰B] kg⁻¹) during the two weeks after thermal neutron irradiation. However, the tumor started to grow thereafter (Fig. 5). In contrast, tumor growth was not suppressed in mice treated with Na[¹⁰B₁₂H₁₁NH₃] solution (100 mg [¹⁰B] kg⁻¹) even after thermal neutron irradiation (Fig. S2, ESI[†]).

Fig. 6 shows the survival curve of tumor-bearing mice after thermal neutron irradiation. All untreated mice without thermal neutron irradiation died within two weeks. Thermal neutron irradiation enhanced mouse survival and all mice exposed to thermal neutron irradiation died within 78 days. Prolonged survival was observed in mice injected with spd-[¹⁰B]- and spd-[¹⁰B₁₂H₁₁NH₃]-encapsulating liposomes; 72% of the mice that received a dose of 15 mg [¹⁰B] kg⁻¹ survived up to 100 days after the thermal neutron irradiation. Furthermore, a remarkable antitumor effect




Fig. 6 Survival curve of tumor-bearing mice after thermal neutron irradiation. The irradiation was performed 36 h after injection of *closo*-dodecaborates (—, spd-BSH: 30 mg [¹⁰B] kg⁻¹; ◆, spd-BSH: 15 mg [¹⁰B] kg⁻¹; ◇, spd-¹⁰B₁₂H₁₁NH₃: 15 mg [¹⁰B] kg⁻¹) for 50 min ($1.3\text{--}2.2 \times 10^{12}$ neutrons per cm²). ×, cold control; ●, hot control. Mice were sacrificed when their tumor volumes reached ~3000 mm³.



was observed in the mice treated with spd-[¹⁰B]-encapsulating liposomes at a dose of 30 mg [¹⁰B] kg⁻¹; 100% of the mice survived up to 100 days after the thermal neutron irradiation.

We succeeded in the preparation of high boron content liposomes. The use of spd as a counter cation of *closo*-dodecaborates was essential to obtain the liposomes with high yields and high B/P ratios. All of the mice injected with 30 mg [¹⁰B] kg⁻¹ of spd-[¹⁰B]-encapsulating liposomes were completely cured while five of seven mice injected with 15 mg [¹⁰B] kg⁻¹ of spd-[¹⁰B]- and spd-[¹⁰B₁₂H₁₁NH₃]-encapsulating liposomes were cured 100 days after thermal neutron irradiation. The results indicate that the total amount of phospholipids could be reduced to less than one-seventh of those used to prepare Na₂[¹⁰B]-encapsulating liposomes.¹⁹ We believe that the spd-*closo*-dodecaborate-encapsulating liposomes are promising candidates for clinical use in BNCT.

We thank Dr S. Kondoh (Teijin Pharm. Co. Ltd) for the measurement of osmotic pressures and Professor K. Iwata (Gakushuin University) for the measurement of the viscosity. This work was supported by Health and Labor Sciences Research Grants for research on Nanotechnical Medical from the Ministry of Health, Labor and Welfare (20100201) and the Ministry of Education, Science, Sports, Culture and Technology, Grant-in-Aid for Scientific Research (B) (No. 23390018) from Japan.

Notes and references

- (a) R. F. Barth, J. A. Coderre, M. G. Vicente and T. E. Blue, *Clin. Cancer Res.*, 2005, **11**, 3987; (b) T. Yamamoto, K. Nakai and A. Matsumura, *Cancer Lett.*, 2008, **262**, 143; (c) H. Hatanaka, *J. Neurol.*, 1975, **209**, 81.
- S.-I. Miyatake, Y. Tamura, S. Kawabata, K. Iida, T. Kuroiwa and K. Ono, *Neurosurgery*, 2007, **61**, 82.
- (a) I. Kato, K. Ono, Y. Sakurai, M. Ohmae, A. Maruhashi, Y. Imahori, M. Kirihata, M. Nakazawa and Y. Yura, *Appl. Radiat. Isot.*, 2004, **61**, 1069; (b) T. Aihara, J. Hiratsuka, N. Morita, M. Uno, Y. Sakurai, A. Maruhashi, K. Ono and T. Harada, *Head Neck*, 2006, **28**, 850; (c) L. Kankaanranta, T. Seppälä, H. Koivunoro, K. Saari-lahti, T. Atula, J. Collan, E. Salli, M. Kortensniemi, J. Uusi-Simola, A. Mäkitie, M. Seppänen, H. Minn, P. Kotiluoto, I. Auterinen, S. Savolainen, M. Kouri and H. Joensuu, *Int. J. Radiat. Oncol., Biol., Phys.*, 2007, **69**, 475.
- (a) Y. Takahashi, Y. Imahori and K. Mineura, *Clin. Cancer Res.*, 2003, **9**, 5888; (b) A. Wittig, W. A. Sauerwein and J. A. Coderre, *Radiat. Res.*, 2000, **153**, 173; (c) G. W. Kabalka and M. L. Yao, *Anticancer Agents Med. Chem.*, 2006, **6**, 111; (d) Y. Imahori, Y. Ohmori, R. Fujii, K. Matsumoto and S. Ueda, *Cancer Res.*, 1995, **55**, 4225.
- M. Suzuki, H. Tanaka, Y. Sakurai, G. Kashino, L. Yong, S. Masunaga, Y. Kinashi, T. Mitsumoto, S. Yajima, H. Tsutsui, T. Sato, A. Maruhashi and K. Ono, *Radiother. Oncol.*, 2009, **92**, 89.
- H. Tanaka, Y. Sakurai, M. Suzuki, T. Takata, S. Masunaga, Y. Kinashi, G. Kashino, Y. Liu, T. Mitsumoto, S. Yajima, H. Tsutsui, M. Takada, A. Maruhashi and K. Ono, *Appl. Radiat. Isot.*, 2009, **67**, S258.
- H. Nakamura, *Future Med. Chem.*, 2013, **5**, 715.
- For passive targeting, see: (a) K. Shelly, D. A. Feakes, M. F. Hawthorne, P. G. Schmidt, T. A. Krisch and W. F. Bauer, *Proc. Natl. Acad. Sci. U. S. A.*, 1992, **89**, 9039; (b) D. A. Feakes, K. Shelly and M. F. Hawthorne, *Proc. Natl. Acad. Sci. U. S. A.*, 1995, **92**, 1367.
- For active targeting, see: (a) H. Yanagië, T. Tomita, H. Kobayashi, Y. Fujii, T. Takahashi, K. Hasumi, H. Nariuchi and M. Sekiguchi, *Br. J. Cancer*, 1991, **63**, 522; (b) H. Yanagië, T. Tomita, H. Kobayashi, Y. Fujii, Y. Nonaka, Y. Saegusa, K. Hasumi, M. Eriguchi, T. Kobayashi and K. Ono, *Br. J. Cancer*, 1997, **75**, 660; (c) X. Q. Pan, H. Wang, S. Shukla, M. Sekido, D. M. Adams, W. Tjarks, R. F. Barth and R. J. Lee, *Bioconjugate Chem.*, 2002, **13**, 435; (d) K. Maruyama, O. Ishida, S. Kasaoka, T. Takizawa, N. Utoguchi, A. Shinohara, M. Chiba, H. Kobayashi, M. Eriguchi and H. Yanagië, *J. Controlled Release*, 2004, **98**, 195.
- Y. Miyajima, H. Nakamura, Y. Kuwata, J.-D. Lee, S. Masunaga, K. Ono and K. Maruyama, *Bioconjugate Chem.*, 2006, **17**, 1314.
- (a) H. Nakamura, Y. Miyajima, T. Takei, S. Kasaoka and K. Maruyama, *Chem. Commun.*, 2004, 1910; (b) J.-D. Lee, M. Ueno, Y. Miyajima and H. Nakamura, *Org. Lett.*, 2007, **9**, 323; (c) M. Ueno, H. S. Ban, K. Nakai, R. Inomata, Y. Kaneda, A. Matsumura and H. Nakamura, *Bioorg. Med. Chem.*, 2010, **18**, 3059.
- (a) T. Li, J. Hamdi and M. F. Hawthorne, *Bioconjugate Chem.*, 2006, **17**, 15; (b) E. Justus, D. Awad, M. Hohnholt, T. Schaffran, K. Edwards, G. Karlsson, L. Damian and D. Gabel, *Bioconjugate Chem.*, 2007, **18**, 1287; (c) X. Pan, G. Wu, W. Yang, R. F. Barth, W. Tjarks and R. J. Lee, *Bioconjugate Chem.*, 2007, **18**, 101.
- P. J. Kueffer, C. A. Maitz, A. A. Khan, S. A. Schuster, N. I. Shlyakhtina, S. S. Jalisatgi, J. D. Brockman, D. W. Nigg and M. F. Hawthorne, *Proc. Natl. Acad. Sci. U. S. A.*, 2013, **110**, 6512.
- H. Koganei, M. Ueno, S. Tachikawa, L. Tasaki, H. S. Ban, M. Suzuki, K. Shiraishi, K. Kawano, M. Yokoyama, Y. Maitani, K. Ono and H. Nakamura, *Bioconjugate Chem.*, 2013, **24**, 124.
- T. Peymann, C. B. Knobler and M. F. Hawthorne, *Inorg. Chem.*, 2000, **39**, 1163.
- W. R. Hertler and M. S. Raasch, *J. Am. Chem. Soc.*, 1964, **86**, 3661.
- (a) D. Gabel, D. Awad, T. Schaffran, D. Radovan, D. Daraban, L. Damian, M. Winterhalter, G. Karlsson and K. Edwards, *Chem-MedChem*, 2007, **2**, 51; (b) D. Awad, L. Damian, M. Winterhalter, G. Karlsson, K. Edwards and D. Gabel, *Chem. Phys. Lipids*, 2009, **157**, 78.
- All protocols were approved by the Institutional Animal Care and Use Committee of Gakushuin University.
- Conventionally, a preinjection of liposome at a high dose was given for an achievement of targeting through saturation of liver's scavenging capacity (see; Y. Y. Kao and R. L. Juliano, *Biochim. Biophys. Acta*, 1981, **677**, 453). Such a high liposome dose may cause possible liver toxicity, since the liver's normal scavenging function is impaired. Indeed, an important character of an approved liposomal formulation (doxil) encapsulating an anticancer drug doxorubicin is the very high concentration of the encapsulated drug (also see; P. G. Tardi, N. L. Boman and P. R. Cullis, *J. Drug Targeting*, 1996, **4**, 129).

